Abstract
Abstrak: Breast cancer is the most common carcinoma in women in the world. Anti-Mullerian Hormone (AMH) is a hormone secreted by primary, secondary, and small antral ovarian follicles of <4mm. The chemotherapy regimen toxic to ovarian follicles is 5-fluorouracil-doxorubicin-cyclophosphamide (FAC). In Indonesia, there had been no study on the effect of FAC chemotherapy on AMH in premenopausal breast carcinoma patients. This study aims to determine the effect of FAC chemotherapy on AMH in premenopausal breast carcinoma patients. This study employed a prospective cohort study design. Inclusion criteria were breast carcinoma, premenopausal, and history of chemotherapy (-). Exclusion criteria were history of ovarian surgery, pelvic radiation, GnRH-agonist therapy, smoking for ≥10 years, obesity, and chemotherapy dropout. Subjects were examined for AMH before the 1st chemotherapy and after the 4th chemotherapy. Statistical test was done with Wilcoxon test, significant if p≤0.05. The average AMH level before FAC chemotherapy was 1.51±1.957; the average AMH level after the 4th FAC chemotherapy was 0.24±0.587. The result of the Wilcoxon test comparing AMH levels before and after 4th FAC chemotherapy was p<0.0001. FAC chemotherapy reduces AMH patients with premenopausal breast carcinoma.Keywords: Breast carcinoma, chemotherapy, AMH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
